Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions

US7431931B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Albert Z. Kapikian · Rockville, US
• Robert M. Chanock · Bethesda, US
• Timo Vesikari · Tampere, FI

Key dates

• Filing date: Jan 26, 2001
• Grant date: Oct 7, 2008
• Expiry date: Jan 24, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2720/12334
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.